Dr. Axe Wire · Study decoded · health

Frankincense Compound Targets Insulin Signaling In Alzheimer's Cell Model

A compound from frankincense resin changed insulin-signaling and inflammation markers in lab-grown neurons exposed to the toxic protein linked to Alzheimer's disease.

By Dr. Axe Editorial Team · October 11, 2026 · 1 source · Watch

Photo: Pexels

A compound found in frankincense resin, incensole acetate, was linked to changes in insulin-signaling and inflammation markers in lab-grown neurons exposed to a toxic brain protein linked to Alzheimer's disease, according to a study published October 2, 2026, in Pharmaceuticals.

Researchers exposed mesenchymal stem cell-derived neurons to amyloid-beta 1-42, the toxic protein fragment associated with Alzheimer's disease, to model the disease in a dish, then treated the cells with incensole acetate, a compound derived from frankincense resin. Treatment was linked to reduced detectable amyloid-beta and changes in insulin-signaling components called INSR, IRS, AKT and AS160. Two sirtuin proteins, SIRT1 and SIRT6, increased with treatment, while a third, SIRT3, showed no significant change. The compound was also linked to reduced NF-kB, a marker of inflammation, and increased NRF2 and PPARα, both tied to cellular stress defense. Separate computer modeling tested how incensole acetate physically binds sirtuin proteins. It bound more weakly than the reference compounds across all three sirtuins in initial docking, though detailed energy calculations showed a more favorable profile for SIRT6, with a binding-energy estimate of -38.26 kcal/mol versus -35.16 for SIRT1 and -30.24 for SIRT3.

Alzheimer's disease involves brain cells losing their ability to respond properly to insulin, a hormone that helps cells manage energy and clear waste proteins. Impaired brain insulin signaling is tied to higher oxidative stress and inflammation, both of which damage neurons over time. The study authors state that incensole acetate was linked to changes in insulin-signaling, sirtuin, inflammatory and oxidative-stress markers in this cell model, while their computational work supports potential interaction with sirtuin proteins without establishing direct sirtuin activation or causal sirtuin-mediated signaling.

Binding Energy of Incensole Acetate Across Three Sirtuin Proteins

Computer simulation, not measured in cells; MM-PBSA binding-energy estimates in kcal/mol

SIRT6 binding energy

-38.26 kcal/mol

SIRT1 binding energy

-35.16 kcal/mol

SIRT3 binding energy

-30.24 kcal/mol

Pharmaceuticals, 2026, Kalkan Cakmak et al.

This is a lab dish study using stem cell-derived neurons, not an animal or human trial, and the authors state that direct sirtuin activation or causal signaling was not established, only association between treatment and marker changes. The paper states it was funded by the University of Health Sciences Turkey and the Scientific and Technological Research Council of Turkey, and that the authors have no conflicts of interest.

Dr. Axe’s Take

Frankincense has a long history in traditional medicine for inflammation, and this lab study hints at a modern mechanism: incensole acetate touches the same insulin-signaling and inflammation pathways that go haywire in Alzheimer's disease. The NF-kB drop alongside the NRF2 rise fits a compound supporting the brain's own antioxidant defenses. This is neurons in a dish, not a person, and the sirtuin binding data came out weaker than the reference compounds in initial testing. I would not call this proof that frankincense protects the brain. I would keep frankincense resin and essential oil in an anti-inflammatory routine generally, pair it with a whole-food, lower-sugar diet for insulin sensitivity, and wait for animal data before drawing conclusions about Alzheimer's protection.

— Dr. Axe

Take the Metabolic Health Quiz →

Study summary

Who: Mesenchymal stem cell-derived neurons exposed to amyloid-beta 1-42 to model Alzheimer's disease; cell culture study, not human or animal subjects
Design: In vitro cellular model combined with computational docking, molecular dynamics simulations and MM-PBSA binding-energy analysis; RT-qPCR, Western blotting and immunofluorescence used to measure markers
Dose: Not reported in the abstract
Primary result: Incensole acetate treatment was linked to reduced detectable amyloid-beta and changes in insulin-signaling proteins INSR, IRS, AKT and AS160; SIRT1 and SIRT6 expression increased, SIRT3 protein levels were not significantly altered
Secondary: NF-kB (inflammation marker) decreased and NRF2 and PPARα (stress-defense markers) increased with treatment; MM-PBSA binding energy estimates were -35.16 kcal/mol for SIRT1, -30.24 for SIRT3 and -38.26 for SIRT6, with a more favorable relative profile for SIRT6 versus the reference ligand
Funding / conflicts: Funding stated in the paper: University of Health Sciences Turkey and the Scientific and Technological Research Council of Turkey. Conflicts stated in the paper: The authors declare no conflicts of interest.
Date: Oct 2, 2026